EA201071316A1 - Иммуномодуляция ингибиторами ингибиторов апоптоза - Google Patents
Иммуномодуляция ингибиторами ингибиторов апоптозаInfo
- Publication number
- EA201071316A1 EA201071316A1 EA201071316A EA201071316A EA201071316A1 EA 201071316 A1 EA201071316 A1 EA 201071316A1 EA 201071316 A EA201071316 A EA 201071316A EA 201071316 A EA201071316 A EA 201071316A EA 201071316 A1 EA201071316 A1 EA 201071316A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- methods
- treating
- immunomodulation
- apoptosis
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 229940088872 Apoptosis inhibitor Drugs 0.000 title 1
- 239000000158 apoptosis inhibitor Substances 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5394708P | 2008-05-16 | 2008-05-16 | |
| PCT/US2009/043874 WO2009140447A1 (en) | 2008-05-16 | 2009-05-14 | Immunomodulation by iap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201071316A1 true EA201071316A1 (ru) | 2011-06-30 |
Family
ID=40823320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201071316A EA201071316A1 (ru) | 2008-05-16 | 2009-05-14 | Иммуномодуляция ингибиторами ингибиторов апоптоза |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9750729B2 (https=) |
| EP (3) | EP2698158B1 (https=) |
| JP (3) | JP5779091B2 (https=) |
| KR (1) | KR20110022608A (https=) |
| CN (1) | CN102099035A (https=) |
| AU (1) | AU2009246347A1 (https=) |
| BR (1) | BRPI0912692A2 (https=) |
| CA (1) | CA2724720A1 (https=) |
| CL (1) | CL2009001195A1 (https=) |
| EA (1) | EA201071316A1 (https=) |
| ES (2) | ES2882855T3 (https=) |
| IL (1) | IL209203A0 (https=) |
| MA (1) | MA32388B1 (https=) |
| MX (1) | MX2010012231A (https=) |
| TW (1) | TW201006834A (https=) |
| WO (1) | WO2009140447A1 (https=) |
| ZA (1) | ZA201008176B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| CN102099035A (zh) * | 2008-05-16 | 2011-06-15 | 诺瓦提斯公司 | Iap抑制剂的免疫调节 |
| JP4995211B2 (ja) * | 2008-09-29 | 2012-08-08 | キヤノン株式会社 | 電子写真画像形成装置 |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| KR20160030099A (ko) * | 2013-06-25 | 2016-03-16 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| AU2017253560B2 (en) * | 2016-04-20 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| CN106496213B (zh) * | 2016-09-30 | 2019-08-20 | 东南大学 | Lcl161前药及其制备方法和应用 |
| WO2020027225A1 (ja) * | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| PH12022550721A1 (en) | 2019-09-25 | 2024-05-13 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2610934B1 (fr) * | 1987-02-13 | 1989-05-05 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
| ES2415336T3 (es) * | 2003-04-11 | 2013-07-25 | Survac Aps | Vacuna terapéutica contra el cáncer |
| CN1938332B (zh) * | 2004-02-04 | 2011-10-19 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
| WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| AU2005228950B2 (en) * | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| US20080234042A1 (en) | 2004-05-02 | 2008-09-25 | Hiroshi Uemura | Game System |
| MX2007010371A (es) * | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| KR20080080131A (ko) | 2005-12-20 | 2008-09-02 | 노파르티스 아게 | Ｉａｐ-억제제와 탁산의 조합물 |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008045905A1 (en) | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as iap inhibitors |
| BRPI0717411A2 (pt) | 2006-10-19 | 2013-11-12 | Novartis Ag | Uso de inibidores de iap |
| AU2007325280B2 (en) * | 2006-11-28 | 2011-03-10 | Dana-Farber Cancer Institute, Inc. | Combination of IAP inhibitors and FLT3 inhibitors |
| EP2126188A1 (en) | 2006-12-26 | 2009-12-02 | Arçelik Anonim Sirketi | A washer / dryer with output from humidity sensor selectively input to control unit |
| WO2008109057A1 (en) * | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| CN102099035A (zh) * | 2008-05-16 | 2011-06-15 | 诺瓦提斯公司 | Iap抑制剂的免疫调节 |
-
2009
- 2009-05-14 CN CN2009801276872A patent/CN102099035A/zh active Pending
- 2009-05-14 ES ES13178264T patent/ES2882855T3/es active Active
- 2009-05-14 MX MX2010012231A patent/MX2010012231A/es not_active Application Discontinuation
- 2009-05-14 EP EP13178264.1A patent/EP2698158B1/en active Active
- 2009-05-14 WO PCT/US2009/043874 patent/WO2009140447A1/en not_active Ceased
- 2009-05-14 EA EA201071316A patent/EA201071316A1/ru unknown
- 2009-05-14 BR BRPI0912692A patent/BRPI0912692A2/pt not_active IP Right Cessation
- 2009-05-14 EP EP09747530.5A patent/EP2296650B1/en active Active
- 2009-05-14 ES ES09747530T patent/ES2791957T3/es active Active
- 2009-05-14 KR KR1020107028375A patent/KR20110022608A/ko not_active Withdrawn
- 2009-05-14 EP EP20159523.8A patent/EP3701947A1/en active Pending
- 2009-05-14 CA CA2724720A patent/CA2724720A1/en not_active Abandoned
- 2009-05-14 JP JP2011509678A patent/JP5779091B2/ja active Active
- 2009-05-14 AU AU2009246347A patent/AU2009246347A1/en not_active Abandoned
- 2009-05-14 US US12/992,631 patent/US9750729B2/en active Active
- 2009-05-15 TW TW098116299A patent/TW201006834A/zh unknown
- 2009-05-15 CL CL2009001195A patent/CL2009001195A1/es unknown
-
2010
- 2010-11-09 IL IL209203A patent/IL209203A0/en unknown
- 2010-11-15 ZA ZA2010/08176A patent/ZA201008176B/en unknown
- 2010-12-08 MA MA33406A patent/MA32388B1/fr unknown
-
2015
- 2015-03-02 JP JP2015040113A patent/JP5986655B2/ja active Active
- 2015-12-03 JP JP2015236482A patent/JP6030739B2/ja active Active
-
2017
- 2017-08-14 US US15/675,987 patent/US10786491B2/en active Active
-
2020
- 2020-07-13 US US16/926,930 patent/US11382905B2/en active Active
-
2022
- 2022-06-06 US US17/832,911 patent/US20220296581A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102099035A (zh) | 2011-06-15 |
| US20110135691A1 (en) | 2011-06-09 |
| CL2009001195A1 (es) | 2010-06-11 |
| US9750729B2 (en) | 2017-09-05 |
| EP2698158A1 (en) | 2014-02-19 |
| US20200345714A1 (en) | 2020-11-05 |
| EP2296650B1 (en) | 2020-05-06 |
| ES2791957T3 (es) | 2020-11-06 |
| TW201006834A (en) | 2010-02-16 |
| WO2009140447A1 (en) | 2009-11-19 |
| ES2882855T3 (es) | 2021-12-02 |
| BRPI0912692A2 (pt) | 2017-03-21 |
| AU2009246347A1 (en) | 2009-11-19 |
| MA32388B1 (fr) | 2011-06-01 |
| MX2010012231A (es) | 2011-02-18 |
| IL209203A0 (en) | 2011-01-31 |
| JP2011524339A (ja) | 2011-09-01 |
| EP2296650A1 (en) | 2011-03-23 |
| EP2698158B1 (en) | 2021-06-30 |
| CA2724720A1 (en) | 2009-11-19 |
| US20220296581A1 (en) | 2022-09-22 |
| JP2015129170A (ja) | 2015-07-16 |
| ZA201008176B (en) | 2011-08-31 |
| JP2016094429A (ja) | 2016-05-26 |
| JP5986655B2 (ja) | 2016-09-06 |
| US10786491B2 (en) | 2020-09-29 |
| US11382905B2 (en) | 2022-07-12 |
| KR20110022608A (ko) | 2011-03-07 |
| EP3701947A1 (en) | 2020-09-02 |
| JP5779091B2 (ja) | 2015-09-16 |
| US20170368047A1 (en) | 2017-12-28 |
| JP6030739B2 (ja) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201071316A1 (ru) | Иммуномодуляция ингибиторами ингибиторов апоптоза | |
| EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
| UA109278C2 (uk) | Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань | |
| MX2012010793A (es) | Composiciones y metodos para la eliminacion de biopeliculas. | |
| UA106640C2 (uk) | Bcl-2-СЕЛЕКТИВНИЙ АПОПТОЗІНДУКУЮЧИЙ ЗАСІБ ДЛЯ ЛІКУВАННЯ РАКУ І ІМУННИХ ЗАХВОРЮВАНЬ | |
| BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
| EA201790413A1 (ru) | Антитела против tigit | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| WO2012045001A3 (en) | Influenza virus antibodies and immunogens and uses therefor | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
| EA201790267A1 (ru) | Новые модуляторы киназ | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
| EA201300131A1 (ru) | Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями |